Influence of beta-endorphin on phytohemagglutinin-induced lymphocyte proliferation and on the expression of mononuclear cell surface antigens in vitro.
Recent evidence suggests that opiates can modulate the immune responses. In particular it has been shown that beta-endorphin and morphine are able to depress some T lymphocyte functions in humans. In the present study, experiments were designed to evaluate the effect of beta-endorphin phytohemagglutinin-induced lymphocyte proliferation and determine the mechanism of this action. The ability of naloxone to block the effect of beta-endorphin was also investigated, and the influence of beta-endorphin on the expression of mononuclear cell surface antigens using the OKT3, OKT4, OKT8, anti-HLA-DR and anti-beta 2-microglobulin monoclonal antibodies was evaluated. Phytohemagglutinin-induced lymphocyte proliferation was significantly inhibited by beta-endorphin. This effect occurred when beta-endorphin was added to cells at the beginning of the culture period (30 min before, simultaneously or 30 min after phytohemagglutinin), but not when added after 48 h of incubation. The preincubation of cells with BEP for 1 h, 4 h or 24 h did not affect lymphocyte activation by phytohemagglutinin. A ten-fold excess of naloxone, added to cultures 30 min prior to beta-endorphin, did not block the inhibitory effect. Incubation with beta-endorphin had different effects on each surface antigen tested. The OKT8+ and beta 2-microglobulin+ cells did not show significant variations. The OKT4+ cells significantly decreased, after 4 h of incubation with beta-endorphin, both in mononuclear cell and in purified T lymphocyte cultures and, after 24 h, in mononuclear cell cultures only. The OKT3+ cells decreased, in mononuclear cell cultures only, after 24 h beta-endorphin incubation.(ABSTRACT TRUNCATED AT 250 WORDS)
Puppo
F
F
Corsini
G
G
Mangini
P
P
Bottaro
L
L
Barreca
T
T
D000911:Antibodies, Monoclonal / Q000276:immunology; D000954:Antigens, Surface; D004723:Endorphins / Q000494:pharmacology*; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II; D006801:Humans; D066298:In Vitro Techniques; D008213:Lymphocyte Activation / Q000187:drug effects*; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D010835:Phytohemagglutinins / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000187:drug effects / Q000276:immunology; D001615:beta-Endorphin
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D004723:Endorphins; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II; D010835:Phytohemagglutinins; D001615:beta-Endorphin